$4.06
+0.32 (+8.56%)
Open$3.73
Previous Close$3.74
Day High$4.11
Day Low$3.69
52W High$5.08
52W Low$1.29
Volume—
Avg Volume449.0K
Market Cap242.06M
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+980.0% upside
Current
$4.06
$4.06
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 153.21M | 154.03M | 19.43M |
| Net Income | -76,469,178 | -69,188,961 | 4.04M |
| Profit Margin | -49.9% | -47.4% | 20.8% |
| EBITDA | -67,298,055 | -64,273,803 | 6.14M |
| Free Cash Flow | — | — | 2.37M |
| Rev Growth | -0.5% | -0.5% | +14.5% |
| Debt/Equity | 1.26 | 1.26 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |